Exelixis, Inc. (EXEL): Price and Financial Metrics
EXEL Price/Volume Stats
Current price | $20.48 | 52-week high | $24.34 |
Prev. close | $20.59 | 52-week low | $16.15 |
Day low | $20.38 | Volume | 2,415,300 |
Day high | $20.84 | Avg. volume | 2,294,764 |
50-day MA | $22.39 | Dividend yield | N/A |
200-day MA | $21.01 | Market Cap | 6.21B |
EXEL Stock Price Chart Interactive Chart >
EXEL POWR Grades
- Value is the dimension where EXEL ranks best; there it ranks ahead of 97.21% of US stocks.
- EXEL's strongest trending metric is Growth; it's been moving up over the last 26 weeks.
- EXEL ranks lowest in Momentum; there it ranks in the 10th percentile.
EXEL Stock Summary
- With a price/earnings ratio of 80.18, EXELIXIS INC P/E ratio is greater than that of about 92.11% of stocks in our set with positive earnings.
- Of note is the ratio of EXELIXIS INC's sales and general administrative expense to its total operating expenses; only 14.25% of US stocks have a lower such ratio.
- Equity multiplier, or assets relative to shareholders' equity, comes in at 1.24 for EXELIXIS INC; that's greater than it is for only 15.04% of US stocks.
- Stocks that are quantitatively similar to EXEL, based on their financial statements, market capitalization, and price volatility, are SLAB, VYGR, CRUS, DRRX, and HYLN.
- EXEL's SEC filings can be seen here. And to visit EXELIXIS INC's official web site, go to www.exelixis.com.
EXEL Valuation Summary
- In comparison to the median Healthcare stock, EXEL's price/sales ratio is 0% higher, now standing at 4.2.
- EXEL's EV/EBIT ratio has moved up 65 over the prior 243 months.
Below are key valuation metrics over time for EXEL.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
EXEL | 2023-12-29 | 4.2 | 3.2 | 81.0 | 59.0 |
EXEL | 2023-12-28 | 4.2 | 3.2 | 81.5 | 59.3 |
EXEL | 2023-12-27 | 4.2 | 3.2 | 81.2 | 59.1 |
EXEL | 2023-12-26 | 4.2 | 3.2 | 81.1 | 59.0 |
EXEL | 2023-12-22 | 4.2 | 3.2 | 80.9 | 58.8 |
EXEL | 2023-12-21 | 4.1 | 3.1 | 79.3 | 57.7 |
EXEL Growth Metrics
- Its year over year price growth rate is now at -14.86%.
- The year over year net income to common stockholders growth rate now stands at 360.14%.
- Its 4 year net income to common stockholders growth rate is now at 8238.51%.
The table below shows EXEL's growth in key financial areas (numbers in millions of US dollars).
Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
---|---|---|---|
2022-12-31 | 1,611.062 | 362.614 | 182.282 |
2022-09-30 | 1,638.285 | 385.372 | 307.621 |
2022-06-30 | 1,554.97 | 358.608 | 272.615 |
2022-03-31 | 1,520.72 | 508.979 | 298.035 |
2021-12-31 | 1,434.97 | 400.804 | 231.063 |
2021-09-30 | 1,253.882 | 337.645 | 164.285 |
EXEL's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- EXEL has a Quality Grade of B, ranking ahead of 93.02% of graded US stocks.
- EXEL's asset turnover comes in at 0.549 -- ranking 297th of 563 Business Services stocks.
- BBSI, QNST, and ROL are the stocks whose asset turnover ratios are most correlated with EXEL.
The table below shows EXEL's key quality metrics over time.
Period | Asset Turnover | Gross Margin | ROIC |
---|---|---|---|
2021-09-30 | 0.549 | 0.961 | 0.128 |
2021-06-30 | 0.525 | 0.960 | 0.071 |
2021-03-31 | 0.486 | 0.961 | 0.045 |
2020-12-31 | 0.479 | 0.963 | 0.088 |
2020-09-30 | 0.479 | 0.961 | 0.129 |
2020-06-30 | 0.520 | 0.963 | 0.248 |
EXEL Price Target
For more insight on analysts targets of EXEL, see our EXEL price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
Average Price Target | $31.77 | Average Broker Recommendation | 1.46 (Moderate Buy) |
Exelixis, Inc. (EXEL) Company Bio
Exelixis is a biopharmaceutical company committed to developing small molecule therapies for the treatment of cancer. The company was founded in 1994 and is based in San Francisco, California.
Latest EXEL News From Around the Web
Below are the latest news stories about EXELIXIS INC that investors may wish to consider to help them evaluate EXEL as an investment opportunity.
11 Stocks Insiders and Billionaires Are Crazy AboutIn this article, we will take a detailed look at the 11 Stocks Insiders and Billionaires Are Crazy About. For a quick overview of such stocks, read our article 5 Stocks Insiders and Billionaires Are Crazy About. In his famous book titled One Up on Wall Street, Peter Lynch talks about how average investors miss out on opportunities by […] |
Is the Options Market Predicting a Spike in Exelixis (EXEL) Stock?Investors need to pay close attention to Exelixis (EXEL) stock based on the movements in the options market lately. |
Why Is Beam Therapeutics Inc. (BEAM) Up 29.5% Since Last Earnings Report?Beam Therapeutics Inc. (BEAM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. |
Exelixis 2023 R&D Day: Science & Strategy to be Webcast on December 12, 2023ALAMEDA, Calif., December 07, 2023--Exelixis, Inc. (Nasdaq: EXEL) today announced that it will webcast the Exelixis 2023 R&D Day: Science & Strategy event taking place on Tuesday, December 12, 2023, from 9:00 a.m. to 12:30 p.m. EST. During the event, featured speakers will review the progress of the company’s growing research and development pipeline, highlight recent clinical updates and elaborate on the company’s continued efforts to serve more patients with cancer and generate sustainable, lo |
Biotech Stock Roundup: EXEL Partners RCUS for Study, PHVS & EYPT Gain on Study DataUpdates from Exelixis (EXEL) and Pharvaris (PHVS) are in the spotlight this week. |
EXEL Price Returns
1-mo | -8.90% |
3-mo | -3.49% |
6-mo | -5.84% |
1-year | 17.10% |
3-year | -7.79% |
5-year | -3.58% |
YTD | -14.63% |
2023 | 49.56% |
2022 | -12.25% |
2021 | -8.92% |
2020 | 13.90% |
2019 | -10.42% |
Continue Researching EXEL
Here are a few links from around the web to help you further your research on Exelixis Inc's stock as an investment opportunity:Exelixis Inc (EXEL) Stock Price | Nasdaq
Exelixis Inc (EXEL) Stock Quote, History and News - Yahoo Finance
Exelixis Inc (EXEL) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...